- 21 health industry groups address FDA on proposed changes to generic drug label rules
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
PITTSBURGH Mylan subsidiary Mylan Technologies has received final approval from the Food and Drug Administration for its hypertension treatment, the generic drug maker said.
Mylan said its clonidine transdermal system USP was approved in the 0.1 mg/day, 0.2 mg/day and 0.3 mg/day strengths. Mylan's CTS is the generic version of Boehringer Ingelheim's Catapres-TTS.
Clonidine transdermal system had U.S. sales of approximately $313 million for the 12 months ended March 31, according to IMS Health. The product is available for immediate shipment.